Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.46), $0.17 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.59 million versus the consensus estimate of $55.1 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $227.7 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.